Stock	New 52-Week Low	Previous 52-Week Low	Previous Date

Alzinova	0.74	0.75	2026-01-13
Betsson B	131.60	131.90	2026-01-14
Embracer Group B	51.10	51.60	2026-01-14
Evolution	581.20	585.20	2026-01-14
Gig Software	3.00	3.80	2025-02-10
Safello	3.45	3.60	2025-12-29
Subgen AI	0.69	0.72	2026-01-13

Source: FactSet

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ALZINOVA AB	0.7310SEK	-0.95%	+3.10%	8.53M
EMBRACER GROUP AB	57.68SEK	+5.89%	+23.95%	1.44B
BETSSON B	88.65SEK	-1.83%	-8.94%	1.36B
SAFELLO GROUP AB	3.340SEK	+4.38%	+1.52%	7.64M

Latest news about Alzinova AB

02-06	48 Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange So Far Today	FW
02-03	Calendar Tuesday, February 3	FW
01-19	Alzinova Engages in In-Depth Partnership Discussions at Healthcare Conference	FW
01-19	16 Stocks Reach New 52-Week Lows Today on the Stockholm Stock Exchange	FW
01-16	Five Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
01-15	Seven Stocks Reach New 52-Week Lows on the Stockholm Stock Exchange Today	FW
01-13	Four Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
12-29	Alzinova's CFO Erik Kullgren Makes Minor Share Purchase	FW
12-29	Nine Stocks Hit New 52-Week Lows Today on the Stockholm Stock Exchange	FW
12-23	Eight Stocks Hit New 52-Week Lows on the Stockholm Stock Exchange Today	FW
12-22	Intrum Takes Billion-Krona Write-Down Amid Mixed Stockholm Stock Exchange; OMXS30 Index Rises 0.1 Percent	FW
12-22	Alzinova raises proceeds of about SEK 50 mln from rights issue	RE
12-22	Alzinova Seeks to Raise Approximately SEK 50 Million Through Rights Issue of Units	FW
12-04	Alzinova enters MoU for commercial partnership in Saudi Arabia	RE
12-04	Alzinova signs letter of intent for partnership in Saudi Arabia	FW

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-25 - Q4 2025 Earnings Release

More about the company